1467 related articles for article (PubMed ID: 28940194)
41. EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms.
van Lengerich B; Agnew C; Puchner EM; Huang B; Jura N
Proc Natl Acad Sci U S A; 2017 Apr; 114(14):E2836-E2845. PubMed ID: 28320942
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
43. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
44. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
[TBL] [Abstract][Full Text] [Related]
45. RhoC mediates epidermal growth factor-stimulated migration and invasion in head and neck squamous cell carcinoma.
Tumur Z; Katebzadeh S; Guerra C; Bhushan L; Alkam T; Henson BS
Neoplasia; 2015 Jan; 17(1):141-51. PubMed ID: 25622907
[TBL] [Abstract][Full Text] [Related]
46. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
[TBL] [Abstract][Full Text] [Related]
47. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.
Paris L; Cecchetti S; Spadaro F; Abalsamo L; Lugini L; Pisanu ME; Iorio E; Natali PG; Ramoni C; Podo F
Breast Cancer Res; 2010; 12(3):R27. PubMed ID: 20462431
[TBL] [Abstract][Full Text] [Related]
49. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases.
Wei Q; Chen L; Sheng L; Nordgren H; Wester K; Carlsson J
Int J Oncol; 2007 Sep; 31(3):493-9. PubMed ID: 17671674
[TBL] [Abstract][Full Text] [Related]
50. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue.
Ekberg T; Nestor M; Engström M; Nordgren H; Wester K; Carlsson J; Anniko M
Int J Oncol; 2005 May; 26(5):1177-85. PubMed ID: 15809707
[TBL] [Abstract][Full Text] [Related]
51. EGFR and HER2 exert distinct roles on colon cancer cell functional properties and expression of matrix macromolecules.
Ellina MI; Bouris P; Aletras AJ; Theocharis AD; Kletsas D; Karamanos NK
Biochim Biophys Acta; 2014 Aug; 1840(8):2651-61. PubMed ID: 24792576
[TBL] [Abstract][Full Text] [Related]
52. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers.
Yen L; Benlimame N; Nie ZR; Xiao D; Wang T; Al Moustafa AE; Esumi H; Milanini J; Hynes NE; Pages G; Alaoui-Jamali MA
Mol Biol Cell; 2002 Nov; 13(11):4029-44. PubMed ID: 12429844
[TBL] [Abstract][Full Text] [Related]
53. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
[TBL] [Abstract][Full Text] [Related]
54. Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.
Ellebaek S; Brix S; Grandal M; Lantto J; Horak ID; Kragh M; Poulsen TT
Int J Cancer; 2016 Nov; 139(9):2095-105. PubMed ID: 27342948
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.
Banappagari S; Corti M; Pincus S; Satyanarayanajois S
J Biomol Struct Dyn; 2012; 30(5):594-606. PubMed ID: 22731912
[TBL] [Abstract][Full Text] [Related]
56. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
57. The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma.
O-charoenrat P; Rhys-Evans PH; Modjtahedi H; Eccles SA
Oral Oncol; 2002 Oct; 38(7):627-40. PubMed ID: 12167415
[TBL] [Abstract][Full Text] [Related]
58. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
Schaefer G; Shao L; Totpal K; Akita RW
Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
[TBL] [Abstract][Full Text] [Related]
59. Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cells.
Ruschel A; Ullrich A
Cell Signal; 2004 Nov; 16(11):1249-61. PubMed ID: 15337524
[TBL] [Abstract][Full Text] [Related]
60. Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response.
Shankaran H; Wiley HS; Resat H
Biophys J; 2006 Jun; 90(11):3993-4009. PubMed ID: 16533841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
